Vijaya Diagnostic Centre Limited (NSE:VIJAYA)
India · Delayed Price · Currency is INR | Market Cap | 131.63B +14.5% |
| Revenue (ttm) | 8.35B +22.5% |
| Net Income | 1.73B +20.9% |
| EPS | 16.79 +20.6% |
| Shares Out | 102.90M |
| PE Ratio | 76.19 |
| Forward PE | 61.24 |
| Dividend | 2.00 (0.16%) |
| Ex-Dividend Date | Aug 29, 2025 |
| Volume | 148,669 |
| Average Volume | 367,181 |
| Open | 1,271.00 |
| Previous Close | 1,279.20 |
| Day's Range | 1,262.00 - 1,297.80 |
| 52-Week Range | 848.00 - 1,375.00 |
| Beta | 0.28 |
| RSI | 76.79 |
| Earnings Date | May 7, 2026 |
About Vijaya Diagnostic Centre
Vijaya Diagnostic Centre Limited provides diagnostic services for patients in India. The company offers laboratory services, including clinical pathology, microbiology, haematology, serology, histopathology, cytogenetics, biochemistry, molecular diagnostics, CT scan, magnetic resonance imaging (MRI) scan, ultrasound, X-ray, cardiology, gastroenterology, nuclear medicine and PET/CT, and MRI-3T services. It also provides health checkups and home sample collection services. Vijaya Diagnostic Centre Limited was founded in 1981 and is based in Hyder... [Read more]
Financial Performance
In fiscal year 2026, Vijaya Diagnostic Centre's revenue was 8.35 billion, an increase of 22.54% compared to the previous year's 6.81 billion. Earnings were 1.73 billion, an increase of 20.90%.
Financial StatementsNews
Vijaya Diagnostic Centre Transcript: Q4 25/26
Q4 FY 2026 saw 26.6% YoY revenue growth and 43.5% EBITDA margin, driven by strong volume and network expansion. FY 2026 revenue crossed INR 800 crore, with robust growth in Hyderabad, Pune, and Kolkata, and continued investment in technology and new centers.
Vijaya Diagnostic Centre Transcript: Q3 25/26
Q3 FY26 saw record revenue of INR 205 crore, up 21.4% year-over-year, with strong growth in both radiology and pathology. EBITDA margin improved to 41.9%, and the wellness segment reached 15% of revenue. Expansion continues with a focus on stabilizing new hubs and investing in technology.
Vijaya Diagnostic Centre Transcript: Q2 25/26
Q2 FY26 saw 10.2% YoY revenue growth and strong margins, led by radiology and new hub launches. Guidance for 15% CAGR and 38-40% EBITDA margin is maintained, with expansion focused on Bengaluru, Kolkata, and tier-two cities.
Vijaya Diagnostic Centre Transcript: Q1 25/26
Q1 FY26 saw 20.4% revenue growth, strong margins, and robust volume gains, with new hubs ramping up well and Hyderabad returning to double-digit growth. Guidance for 15%+ revenue growth and 38%-39% EBITDA margin is maintained, with continued expansion and market share gains in new geographies.
Vijaya Diagnostic Centre Transcript: Q4 24/25
Q4 FY25 revenue grew 12% YoY to INR 173 crores, with strong organic growth and healthy margins. Expansion continues with 10 new hubs planned for FY26 and a CapEx of INR 140-150 crores. EBITDA margin is expected to dip 1-2% for a few quarters due to new center ramp-up, then normalize.
Vijaya Diagnostic Centre Transcript: Q3 24/25
Q3 FY25 saw 27% revenue growth (20% organic), with strong volume gains and robust margins. Expansion continues with 14 new hubs planned, a stable net cash position, and a 15% CAGR target, though near-term margins may dip slightly as new centers ramp up.
Vijaya Diagnostic Centre Transcript: Q2 24/25
Q2 FY25 saw 32% revenue growth (23% organic), driven by strong volume and B2C focus, with EBITDA margin at 41.5%. Expansion continues with new hubs and tech upgrades, while maintaining a debt-free balance sheet and robust cash position.
Vijaya Diagnostic Centre Transcript: Q1 24/25
Q1FY25 saw 29% YoY revenue growth, strong margins (39% EBITDA), and robust expansion with nine new hubs planned. B2C and wellness segments performed well, and all but one new hub are EBITDA positive. Expansion is funded internally, with margins expected to remain stable.